Literature DB >> 30857653

Occurrence of a primary liver cancer with an unusual histologic appearance as a late Fontan complication.

Taka-Aki Matsuyama1, Hideo Ohuchi2, Koji Saito3, Fukuo Kondo3, Toshio Fukusato3, Hatsue Ishibashi-Ueda4.   

Abstract

The Fontan procedure is an open heart procedure performed in pediatric patients with a particular congenital cardiac anomaly known as a univentricular heart. The procedure is used to reroute the systemic venous blood from the inferior vena cava directly to the pulmonary artery. It improves patients' prognoses, but various late-phase extracardiac complications that manifest when patients reach adolescence have been recognized. These complications, pulmonary arteriovenous fistula and protein losing gastroenteropathy, for example, present significant challenges in the management of adults with Fontan circulation. Liver fibrosis is another possible late-phase complication and one of the most serious. Development of a neoplasm, usually a hepatocellular carcinoma, is sometimes reported. We encountered a young patient in whom Fontan circulation led to the development of a histologically unusual liver cancer that resembled the poorly differentiated hepatocellular carcinoma or the combined hepatocellular-cholangiocarcinoma with stem-cell features described in the latest WHO classification.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Congenital cardiac anomaly; Congestion; Extracardiac complication; Fontan procedure; Liver cancer; Liver fibrosis

Mesh:

Year:  2019        PMID: 30857653     DOI: 10.1016/j.prp.2019.02.016

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  1 in total

1.  Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer.

Authors:  Liang Shao; Xiaolei Wang; Yongtao Yu; Jiangwei Xie
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.